Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
The enhancements will improve environmental sustainability, strengthen material governance, and boost utility reliability
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The company’s total income jumped 31% year-on-year to Rs 125.5 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
